Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Open Access

Prognostic factors related to dendritic cell vaccines on patients with advanced non-small cell lung cancers: a multicenter analysis

  • Hidenori Takahashi1,
  • Shigetaka Shimodaira2,
  • Masahiro Ogasawara3,
  • Masanori Kobayashi4,
  • Hirofumi Abe5,
  • Kazuhiro Nagai6,
  • Sunichi Tsujitani7,
  • Masato Okamoto8,
  • Yuji Morita9 and
  • Yoshikazu Yonemitsu10
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P451

DOI: 10.1186/2051-1426-3-S2-P451

Published: 4 November 2015

Objective

Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced non-small cell lung cancers (NSCLCs). However, variations among clinical studies make it difficult to compare clinical outcomes. J-SICT DC vaccine study group is composed of the multi-medical centers in Japan, has provided DC vaccines as a compassionate use under the unified regimens for cell production and patient treatment, and published a number of clinical data of patients treated with DC vaccines. A single medical institution of this group has recently published a potentially beneficial effect of DC vaccines on overall survival of 62 patients with advanced NSCLCs[1]. Here we extended the findings to 260 patients with advanced NSCLCs who treated among 6 centers of this group.

Methods

Of 337 patients who met the inclusion criteria, 260 patients who received by weekly more than 5-times of peptide-pulsed DC vaccines were analyzed.

Results

No serious adverse event related to DC vaccination. The mean survival time from diagnosis was 33.0 months (95%CI=27.9–39.2, 85.5% in 1-year and 66.4% in 2-years), and that from the first vaccination was 13.8 months (95%CI=11.4–16.8, 53.5% in 1-year and 36.1% in 2-years). Similar to our previous findings obtained in the analysis for advanced pancreatic cancer[2], 30 mm and more in diameter of erythema reaction at the injected site was identified as the strongest factor correlating to the overall survival from 1st vaccine (> 30 mm: MST=20.4 months, n=135 and < 30 mm: MST=8.8 months, n=122, p < 0.0001) in uni- and multivariate analyses. Importantly, the size of erythema reaction was significantly correlated with ECOG-PS, neutrophil/lymphocyte (N/L) ratio, hemoglobin, C-reactive protein, and fever (over 38 oC) at the time of leukapheresis, suggesting that the good physical condition as well as less inflammatory reaction might be important to induce stronger reaction against DC vaccines.

Conclusions

This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of DC vaccines in patients with advanced NSCLCs. These findings suggest the potential responders against DC vaccines, and need to be addressed in well-controlled prospective randomized trials.

Authors’ Affiliations

(1)
Seren Clinic Fukuoka
(2)
Cell Processing Center, Shinshu University Hospital
(3)
Department of Hematology, Sapporo Hokuyu Hospital
(4)
Seren Clinic Nagoya
(5)
Seren Clinic Kobe
(6)
Transfusion and Cell Therapy Unit, Nagasaki University Hospital
(7)
Cancer Center, Tottori University Hospital
(8)
Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy
(9)
Seren Clinic Tokyo
(10)
R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences, Kyushu University

References

  1. Takahashi H, et al: Eur J Cancer. 2013, 49: 852-9.PubMedView ArticleGoogle Scholar
  2. Kobayashi M, et al: Cancer Immunol Immunother. 2014, 63: 797-806.PubMedView ArticleGoogle Scholar

Copyright

© Takahashi et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement